Dow Jones
39.372,92 +316,53 (+0,81%) Nasdaq
16.348,29 +45,54 (+0,28%) Nikkei 225
38.073,98 -128,39 (-0,34%) EUR/USD
1,0784 +0,0032 (+0,30%) Bitcoin EUR
57.704,52 -235,66 (-0,41%) CMC Crypto 200
1.339,70 +39,60 (+3,05%)
InterCure Ltd. (INCR)
| Chiusura precedente | 3,3200 |
| Aperto | 3,2800 |
| Denaro | 3,2000 x 100 |
| Lettera | 3,3300 x 100 |
| Min-Max giorno | 3,1800 - 3,3400 |
| Intervallo di 52 settimane | 0,9900 - 3,7200 |
| Volume | |
| Media Volume | 73.316 |
| Capitalizzazione | 148,111M |
| Beta (5 anni mensile) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,3600 |
| Prossima data utili | 01 apr 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 33,76 |
GlobeNewswireInterCure Announces Record Revenues First Half of 2023 with over 14% growth YOY
Half Year Revenues 2020 to 2023 Half Year Revenues 2020 to 2023 Achieved record revenues of NIS 209 million ($75 million)1 for the first half of 2023 Annualized revenue run rate of NIS 417 million ($149 million) Adjusted EBITDA2 of NIS 30 million ($11 million) Generated NIS 35 million ($13 million) cash from operations in the second quarter Strong balance sheet with over NIS 116 million ($42 million) cash and financial assets3 of NIS 71 million ($25 million) NEW YORK and HERZLIYA, Israel, Aug. 3
GlobeNewswireInterCure Ltd. Announces Proposed Voluntary Delisting from the Toronto Stock Exchange and shall continue to be listed on the NASDAQ and TASE
NEW YORK and TORONTO and HERZLIYA, Israel, July 10, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the "Company"), announced today that its board of directors (“Board”) has approved the voluntarily delisting of the Company’s common shares (“Shares”) from the Toronto Stock Exchange (the “TSX”) (the “Delisting”). The Company has decided to delist from the TSX after concluding that maintaining the listing does not offer substantial ben
- GlobeNewswire
InterCure Provides an Update About The Lawsuit it Filed Against Cann Pharmaceuticals to Recover Funds Following Failed Merger
NEW YORK and TORONTO and HERZLIYA, Israel, June 09, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the "Company"), reports today that, further to the Company’s press release issued on February 1, 2023, where the Company had reported the termination of the merger agreement (the “Agreement”) with Cann Pharmaceutical Ltd. ("Better") due to fundamental disagreements between the parties thereto and that the closing conditions contained i
